Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 14
- Registration Number
- NCT04509622
- Locations
- 🇯🇵
NTT Medical Center Tokyo /ID# 223574, Shinagawa-ku, Tokyo, Japan
🇯🇵Okayama University Hospital /ID# 222990, Okayama-shi, Okayama, Japan
🇯🇵NHO Nagoya Medical Center /ID# 223671, Nagoya-shi, Aichi, Japan
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 2
- Registration Number
- NCT04425655
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Mixed Phenotype Acute LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Undifferentiated Leukemia
- Interventions
- Drug: CyclophosphamideDrug: CladribineDrug: CyclosporineDrug: CytarabineBiological: FilgrastimProcedure: Hematopoietic Cell TransplantationDrug: MitoxantroneDrug: IdarubicinDrug: Mycophenolate MofetilDrug: FludarabineDrug: Mycophenolate SodiumRadiation: Total-Body IrradiationProcedure: Multigated Acquisition ScanProcedure: EchocardiographyProcedure: X-Ray ImagingProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT04375631
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT04354025
AflacLL1901 (CHOA-AML)
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 8
- Registration Number
- NCT04326439
- Locations
- 🇺🇸
Egleston Hospital, Atlanta, Georgia, United States
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: AsparaginaseDrug: Asparaginase Erwinia chrysanthemiProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyBehavioral: Cogstate Assessment BatteryProcedure: Computed TomographyDrug: CytarabineDrug: EtoposideDrug: Dexrazoxane HydrochlorideDrug: Daunorubicin HydrochlorideOther: Fludeoxyglucose F-18Drug: Gemtuzumab OzogamicinDrug: Gilteritinib FumarateDrug: Liposome-encapsulated Daunorubicin-CytarabineDrug: MethotrexateProcedure: Magnetic Resonance ImagingDrug: Mitoxantrone HydrochlorideProcedure: Positron Emission TomographyDrug: Therapeutic Hydrocortisone
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1400
- Registration Number
- NCT04293562
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
- Conditions
- Interventions
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT04275518
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳The First Affilated Hospital of Ganzhou Medical University, Suzhou, Jiangsu, China
🇨🇳Guangzhou panyu central hospital, Guangzhou, Guangdong, China
Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 34
- Registration Number
- NCT04254640
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 25
- Registration Number
- NCT04250051
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT04240002
- Locations
- 🇩🇪
Site DE49001, Halle (Saale), Sachsen-Anhalt, Germany
🇮🇹SIte IT39001, Roma, Italy
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.